HK1214134A1 - 醋酸格拉替雷的透粘膜给药 - Google Patents
醋酸格拉替雷的透粘膜给药 Download PDFInfo
- Publication number
- HK1214134A1 HK1214134A1 HK16102020.2A HK16102020A HK1214134A1 HK 1214134 A1 HK1214134 A1 HK 1214134A1 HK 16102020 A HK16102020 A HK 16102020A HK 1214134 A1 HK1214134 A1 HK 1214134A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tablet
- oral tablet
- amount
- present
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745226P | 2012-12-21 | 2012-12-21 | |
| US61/745,226 | 2012-12-21 | ||
| PCT/US2013/077034 WO2014100639A1 (en) | 2012-12-21 | 2013-12-20 | Transmucosal delivery of glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1214134A1 true HK1214134A1 (zh) | 2016-07-22 |
Family
ID=50979257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102020.2A HK1214134A1 (zh) | 2012-12-21 | 2013-12-20 | 醋酸格拉替雷的透粘膜给药 |
| HK16102544.9A HK1214523A1 (zh) | 2012-12-21 | 2013-12-20 | 醋酸格拉替雷的透粘膜给药 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102544.9A HK1214523A1 (zh) | 2012-12-21 | 2013-12-20 | 醋酸格拉替雷的透粘膜给药 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160193276A1 (enExample) |
| EP (1) | EP2934492A4 (enExample) |
| JP (1) | JP2016503803A (enExample) |
| KR (1) | KR20150111918A (enExample) |
| CN (1) | CN104869983A (enExample) |
| AU (1) | AU2013361053A1 (enExample) |
| BR (1) | BR112015014095A2 (enExample) |
| CA (1) | CA2895359A1 (enExample) |
| EA (1) | EA201591188A1 (enExample) |
| HK (2) | HK1214134A1 (enExample) |
| IL (1) | IL239280A0 (enExample) |
| MX (1) | MX2015007678A (enExample) |
| SG (1) | SG11201504422XA (enExample) |
| WO (1) | WO2014100639A1 (enExample) |
| ZA (1) | ZA201505049B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| CA2851510A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2015140790A1 (en) | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| CN106924175B (zh) * | 2015-12-29 | 2020-07-03 | 深圳翰宇药业股份有限公司 | 一种治疗多发性硬化症的药物组合物 |
| TWI781921B (zh) * | 2016-02-12 | 2022-11-01 | 日商特一華製藥股份有限公司 | 乾式造粒物及含有該乾式造粒物之固形製劑以及其製造方法 |
| CN110996983A (zh) | 2017-06-26 | 2020-04-10 | 巴斯德研究所 | 清除hiv储库并降低病毒载量的治疗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200206457B (en) * | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| MXPA02008023A (es) * | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| IL159715A0 (en) * | 2001-07-10 | 2004-06-20 | Teva Pharma | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| PT1848415E (pt) * | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
| CA2623018A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of telmisartan |
| BRPI0620578A2 (pt) * | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| PT2201840E (pt) * | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
-
2013
- 2013-12-20 KR KR1020157019729A patent/KR20150111918A/ko not_active Withdrawn
- 2013-12-20 CN CN201380067083.XA patent/CN104869983A/zh active Pending
- 2013-12-20 WO PCT/US2013/077034 patent/WO2014100639A1/en not_active Ceased
- 2013-12-20 HK HK16102020.2A patent/HK1214134A1/zh unknown
- 2013-12-20 AU AU2013361053A patent/AU2013361053A1/en not_active Abandoned
- 2013-12-20 CA CA2895359A patent/CA2895359A1/en not_active Abandoned
- 2013-12-20 HK HK16102544.9A patent/HK1214523A1/zh unknown
- 2013-12-20 BR BR112015014095A patent/BR112015014095A2/pt not_active IP Right Cessation
- 2013-12-20 MX MX2015007678A patent/MX2015007678A/es unknown
- 2013-12-20 EA EA201591188A patent/EA201591188A1/ru unknown
- 2013-12-20 SG SG11201504422XA patent/SG11201504422XA/en unknown
- 2013-12-20 JP JP2015549792A patent/JP2016503803A/ja not_active Withdrawn
- 2013-12-20 US US14/653,022 patent/US20160193276A1/en not_active Abandoned
- 2013-12-20 EP EP13865051.0A patent/EP2934492A4/en not_active Withdrawn
-
2015
- 2015-06-08 IL IL239280A patent/IL239280A0/en unknown
- 2015-07-14 ZA ZA2015/05049A patent/ZA201505049B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014100639A1 (en) | 2014-06-26 |
| KR20150111918A (ko) | 2015-10-06 |
| CN104869983A (zh) | 2015-08-26 |
| AU2013361053A1 (en) | 2015-07-30 |
| BR112015014095A2 (pt) | 2017-07-11 |
| JP2016503803A (ja) | 2016-02-08 |
| SG11201504422XA (en) | 2015-07-30 |
| CA2895359A1 (en) | 2014-06-26 |
| IL239280A0 (en) | 2015-07-30 |
| MX2015007678A (es) | 2015-09-07 |
| EP2934492A4 (en) | 2016-08-17 |
| EP2934492A1 (en) | 2015-10-28 |
| EA201591188A1 (ru) | 2016-04-29 |
| ZA201505049B (en) | 2016-10-26 |
| US20160193276A1 (en) | 2016-07-07 |
| HK1214523A1 (zh) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6657454B2 (ja) | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス | |
| HK1214134A1 (zh) | 醋酸格拉替雷的透粘膜给药 | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| CN104812378B (zh) | 固体剂型 | |
| ES2862573T3 (es) | Formulaciones de nalbufina de liberación sostenida | |
| ES2898348T3 (es) | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa | |
| TW200815048A (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| Raju et al. | Formulation and in-vitro evaluation of buccal tablets of metoprolol tartrate | |
| EP1750677A1 (en) | Oral therapeutic compound delivery system | |
| JP2016535778A (ja) | 乱用抑止性剤形 | |
| WO2016081676A1 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| CN116615243A (zh) | 使用右美托咪啶盐酸盐治疗躁郁症和精神病 | |
| CN101784263A (zh) | 奈韦拉平的延长释放制剂 | |
| US20040122065A1 (en) | Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally | |
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| KR102669683B1 (ko) | 장세척을 위한 경구용 고형제제 | |
| US20110021542A1 (en) | Use of a Combination of Udenafil and Alfuzosin or Oxybutynin for the Treatment of Overactive Bladder | |
| Michel | A benefit-risk assessment of extended-release oxybutynin | |
| US20050281873A1 (en) | Universal controlled-release composition | |
| KR20170086053A (ko) | 디메틸 푸마르산염을 포함하는 제약학적 매트릭스 제제 | |
| US20160310434A1 (en) | Gastro-retentive oral pharmaceutical compositions | |
| WO2019018338A1 (en) | NASAL COMPOSITION COMPRISING A MUCOADHESIVE POLYMER | |
| US11096890B2 (en) | Chewable dosage forms containing sitagliptin and metformin | |
| JP2012502042A (ja) | Ｈｉｖ結合阻害剤の最適な送達のための安定な医薬組成物 | |
| Do | In situ forming implants for the treatment of periodontitis |